Effects of weight loss on heart health in obese patients with heart failure
The Effects of Obesity and Weight Loss in Heart Failure: Imaging the Obesity Paradox Using Magnetic Resonance Imaging and Spectroscopy - Heart Failure With Preserved Ejection Fraction Substudy
This study tests if losing weight can help improve heart health in overweight or obese people with heart failure.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Oxford) |
| Trial ID | NCT05878912 on ClinicalTrials.gov |
What this trial studies
This study investigates how weight loss impacts individuals with heart failure with preserved ejection fraction (HFpEF) who are overweight or obese. Participants will be randomly assigned to either a diet intervention or a control group receiving standard care. The study will assess various outcomes, including heart function, quality of life, and exercise capacity through a series of measurements such as echocardiograms, MRIs, and questionnaires. The study aims to determine if weight loss can improve heart shape and pumping efficiency in this patient population.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with heart failure with preserved ejection fraction and a BMI of 27.5 kg/m² or higher.
Not a fit: Patients with contraindications to MRI or those with severe heart conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved heart function and quality of life for patients with HFpEF who are overweight or obese.
How similar studies have performed: Other studies have shown promising results in weight loss interventions for heart failure patients, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Heart failure with preserved ejection fraction (HFpEF) * Left ventricular ejection fraction (LVEF) =/\> 50% * Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2 Exclusion Criteria: * Contraindications to magnetic resonance imaging * NYHA class IV * Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease * Pregnancy, planned pregnancy or lactating * Any other conditions which may potentially compromise the safety or scientific validity of the study
Where this trial is running
Oxford
- Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital — Oxford, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Oliver J Rider, DPhil — University of Oxford
- Study coordinator: Jiliu Pan, BMBCh
- Email: jiliu.pan@cardiov.ox.ac.uk
- Phone: +44(0)1865234591
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.